Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:1969
doi: 10.1161/CIRCULATIONAHA.107.182500
Free Article
This Article
Free upon publication Free Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Articles

(Circulation. 2007;115:1969.)
© 2007 American Heart Association, Inc.

Issue Highlights


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    OPTIMAL TREATMENT OF OBESITY-RELATED HYPERTENSION: THE HYPERTENSION-OBESITY-SIBUTRAMINE (HOS) STUDY, by Scholze et al.
 
This article by Scholze and colleagues provides much-needed guidance on how to deal with the obese patient with mild hypertension (147/93 mm Hg on randomization). The entry point is the use of the weight-reducing drug sibutramine, which achieved weight loss at the cost of a small increase in 24-hour diastolic blood pressure. To control the blood pressure and to annul this increase, 3 combination antihypertensive therapies were used, 2 of them a calcium channel blocker and an angiotensin-converting enzyme inhibitor, and the third a ß-blocker plus diuretic combination. Sibutramine led to weight loss and improved glucose tolerance. These benefits were abrogated in the cohort treated by the ß-blocker-diuretic, as compared with both calcium channel blocker–angiotensin-converting enzyme inhibitor regimes. Triglyceride levels were reduced with sibutramine but not with placebo. Thus, when treating overweight hypertensive patients by sibutramine, blood pressure reduction by a calcium channel blocker–angiotensin-converting enzyme inhibitor regimen is preferred to a ß-blocker-diuretic regimen. See p 1991.


*    INFARCT TISSUE HETEROGENEITY BY MAGNETIC RESONANCE IMAGING IDENTIFIES ENHANCED CARDIAC ARRHYTHMIA SUSCEPTIBILITY IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION, by Schmidt et al.
 
In recent years, the ability to define carefully the presence, extent, and transmurality of infarct has been strongly validated using noninvasive cardiac magnetic resonance (CMR) imaging. More recently in Circulation, investigators began to explore the ability of CMR to define a border zone surrounding an infarct, likely representing an admixture of viable and infarcted tissue, showing that the presence of such a border zone was associated with an adverse prognosis. Those data suggested the possibility that the border zone represents a milieu for arrhythmia generation. In this issue of Circulation, Schmidt . . . [Full Text of this Article]


Related Articles:

Neonatal Tuberous Sclerosis and Multiple Cardiac Arrhythmias
Yaniv Bar-Cohen, Michael J. Silka, and Mark S. Sklansky
Circulation 2007 115: e395-e397. [Extract] [Full Text]

Definitive Diagnosis of Pulmonary Artery Sling in a Critically Ill Infant With High-Resolution Computed Tomography
Phalla Ou, David S. Celermajer, Gabriella Agnoletti, Francis Brunelle, Pascal Vouhé, Daniel Sidi, and Damien Bonnet
Circulation 2007 115: e398-e399. [Extract] [Full Text]

Percutaneous Closure of a False Aneurysm of the Right Ventricle in a Congenital Heart Disease Patient
Gabriella Agnoletti, Laurence Iserin, Elena Rizzo, and Elie Mousseaux
Circulation 2007 115: e400-e402. [Extract] [Full Text]

Letter by Padfield et al Regarding Article, "Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) Study"
Gareth J. Padfield, Nathaniel M. Hawkins, and Michael R. MacDonald
Circulation 2007 115: e403. [Extract] [Full Text]

Optimal Treatment of Obesity-Related Hypertension: The Hypertension-Obesity-Sibutramine (HOS) Study
Jürgen Scholze, Elmar Grimm, Dana Herrmann, Thomas Unger, and Ulrich Kintscher
Circulation 2007 115: 1991-1998. [Abstract] [Full Text]

Infarct Tissue Heterogeneity by Magnetic Resonance Imaging Identifies Enhanced Cardiac Arrhythmia Susceptibility in Patients With Left Ventricular Dysfunction
André Schmidt, Clerio F. Azevedo, Alan Cheng, Sandeep N. Gupta, David A. Bluemke, Thomas K. Foo, Gary Gerstenblith, Robert G. Weiss, Eduardo Marbán, Gordon F. Tomaselli, João A.C. Lima, and Katherine C. Wu
Circulation 2007 115: 2006-2014. [Abstract] [Full Text]

Clinical Aspects and Prognosis of Brugada Syndrome in Children
Vincent Probst, Isabelle Denjoy, Paola G. Meregalli, Jean-Christophe Amirault, Fréderic Sacher, Jacques Mansourati, Dominique Babuty, Elisabeth Villain, Jacques Victor, Jean-Jacques Schott, Jean-Marc Lupoglazoff, Philippe Mabo, Christian Veltmann, Laurence Jesel, Philippe Chevalier, Sally-Ann B. Clur, Michel Haissaguerre, Christian Wolpert, Hervé Le Marec, and Arthur A.M. Wilde
Circulation 2007 115: 2042-2048. [Abstract] [Full Text]